New T cell immune response discovery points to 'out-of-box' cancer therapy options
Researchers have identified a class of T cells with an unconventional tumor-homing mechanism that could point the way to new types of cancer immunotherapies.
In immune checkpoint therapy, monoclonal antibodies prevent PD-1, a “checkpoint protein” on certain tumors from binding to the T cell and turning the T cell off. The T cells can thus remain on and destroy cancerous cells presenting with certain tumor antigens.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.